Literature DB >> 12482638

Role of protein kinase C-angiotensin II pathway for extracellular matrix production in cultured human mesangial cells exposed to high glucose levels.

Kayoko Ikehara1, Hisaya Tada, Koji Kuboki, Toshiki Inokuchi.   

Abstract

The intrarenal renin-angiotensin system has been implicated in the pathogenesis of diabetic nephropathy. This study investigates the mechanisms for glucose-induced increase in angiotensin II (AII) production by human mesangial cells (MCs) in relation to protein kinase C (PKC). We also examine whether locally produced AII mediates extracellular matrix protein production in high-glucose conditions. Human MCs were cultured in 5 or 33 mmol/l glucose for 8 days, and were incubated with or without 5 mmol/l GFX, a PKC inhibitor, 0.1 micromol/l candesartan cilexetil (CC), a specific type 1 AII receptor antagonist, for another 24 h. In addition, MCs grown in 5 mmol/l glucose were incubated with 0.1 micromol/l phorbol-12,13-dibutyrate (PDBu) for 24 h. AII, TGF-beta1, fibronectin and type IV collagen in the culture media were measured by ELISA. The amount of AII secreted from MCs exposed to high-glucose levels was significantly greater (P<0.01) than that in normal glucose levels. The increase in AII production was completely prevented by GFX. The addition of PDBu mimicked the effect of glucose on AII production. The glucose-induced increases in the production of TGF-beta1, fibronectin and type IV collagen were partially, but significantly restored (P<0.01) by CC, while GFX totally abolished these effects of glucose. These results suggest that elevated glucose levels stimulate AII production via mechanisms dependent on glucose-induced PKC activation in human MCs, and that locally produced AII partly mediates the increase in mesangial matrix synthesis in high-glucose conditions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12482638     DOI: 10.1016/s0168-8227(02)00194-8

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  7 in total

Review 1.  Antiproteinuric effect of RAS blockade: new mechanisms.

Authors:  Markus Lassila; Mark E Cooper; Karin Jandeleit-Dahm
Journal:  Curr Hypertens Rep       Date:  2004-10       Impact factor: 5.369

2.  The renin inhibitor aliskiren attenuates high-glucose induced extracellular matrix synthesis and prevents apoptosis in cultured podocytes.

Authors:  Lynetta M Phillips; Ying Wang; Tiane Dai; David L Feldman; Janine LaPage; Sharon G Adler
Journal:  Nephron Exp Nephrol       Date:  2011-01-11

3.  Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade.

Authors:  Genei Ihara; Hideyasu Kiyomoto; Hiroyuki Kobori; Yukiko Nagai; Naro Ohashi; Hirofumi Hitomi; Daisuke Nakano; Nicolas Pelisch; Taiga Hara; Takefumi Mori; Sadayoshi Ito; Masakazu Kohno; Akira Nishiyama
Journal:  J Hypertens       Date:  2010-11       Impact factor: 4.844

4.  Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells.

Authors:  S Giunti; G H Tesch; S Pinach; D J Burt; M E Cooper; P Cavallo-Perin; G Camussi; G Gruden
Journal:  Diabetologia       Date:  2007-10-30       Impact factor: 10.122

5.  Angiotensin II- and glucose-stimulated extracellular matrix production: mediation by the insulin-like growth factor (IGF) axis in a murine mesangial cell line.

Authors:  Lori K Davis; Buel D Rodgers; Kevin M Kelley
Journal:  Endocrine       Date:  2008-04-08       Impact factor: 3.633

6.  Valsartan blocks thrombospondin/transforming growth factor/Smads to inhibit aortic remodeling in diabetic rats.

Authors:  Hui Sun; Yong Zhao; Xiuping Bi; Shaohua Li; Guohai Su; Ya Miao; Xiao Ma; Yun Zhang; Wei Zhang; Ming Zhong
Journal:  Diagn Pathol       Date:  2015-04-02       Impact factor: 2.644

Review 7.  Thrombospondin-1: A Key Protein That Induces Fibrosis in Diabetic Complications.

Authors:  Linhao Xu; Yong Zhang; Jian Chen; Yizhou Xu
Journal:  J Diabetes Res       Date:  2020-06-11       Impact factor: 4.011

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.